期刊
ONCOTARGET
卷 7, 期 13, 页码 15460-15473出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7102
关键词
breast cancer; interleukin-6; gp130
资金
- National Institutes of Health [R01 CA127645, R01 AT007036]
- National Institutes of Environmental Health Sciences [ES005022]
- Trustees Research Fellowship Program at Rutgers
- State University of New Jersey
- Basic Science Research Program through National Research Foundation of Korea (NRF) - Ministry of Education [2013R1A1A2009176]
- Bio & Medical Technology Development Program of the NRF - Ministry of Science, ICT, & Future Planning [NRF-2013M3A9B5075839]
- Catholic University of Korea
- National Research Foundation of Korea [2013R1A1A2009176] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Interleukin-6 (IL-6) is a pleiotropic cytokine with known multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling. Emerging evidence suggests that high levels of IL-6 are correlated with poor prognosis in breast cancer patients. IL-6 appears to play a critical role in the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells (BCSCs), and drug resistance of BCSCs, making anti-IL-6/IL-6R/gp130 therapies promising options for the treatment and prevention of breast cancers. However, preclinical and clinical studies of the applications of anti-IL-6/IL-6R/gp130 therapy in breast cancers are limited. In this review, we summarize the structures, preclinical and clinical studies, mechanisms of action of chemical and biological blockers that directly bind to IL-6, IL-6R, or gp130, and the potential clinical applications of these pharmacological agents as breast cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据